Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Biomarker Validation for Genomic Assays
Assay Developers Put Their Tests to the Test and Demonstrate the Clinical Utility of Genomic Biomarkers
For full access to this article login to GEN Select now.
Making Bioprocess Scale-Up More Robust
Getting It Right Involves More Than Simply Multiplying Vessel Size and Equipment
- Disposable bioprocessing, platform expression and purification technologies, and a higher level of bioprocess understanding have made scale-up more robust and predictable, but not quite automatic. Communication between lab and pilot-scale personnel is critical for successful scale-up, says Klaus Graumann, Ph.D., head of technical development at Sandoz. The company’s ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.